+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical Regions, Key Players and Sales Forecast

  • PDF Icon

    Report

  • 640 Pages
  • May 2024
  • Region: Global
  • Roots Analysis
  • ID: 5691623

Rising Leukemia and Lymphoma Cases Boost CAR T Cell Therapy Market, with Positive Phase III Trials Expanding Treatment Potential

The global CAR T cell therapy market is likely to be worth USD 4.6 billion in 2024, and is projected to reach worth USD 25 billion by 2035, growing at a CAGR of 16.6% during the period 2024-2035.

The new research study consists of industry trends, detailed market analysis, funding and investments analysis, and clinical trial analysis. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the CAR T cell therapy market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.

Cancer is one of the leading causes of deaths, globally. In fact, as per World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on the affected individuals, their families, communities as well as the national health systems., Presently, there are several conventional approaches, including chemotherapy, radiation therapy and surgery that are used for the treatment of various cancers. However, among the several treatment options that are available to control disease progression and prevent malignant cells from spreading throughout the body, lasting remission is still difficult to achieve.

In order to mitigate the existing challenges related with the conventional treatment approaches, various active initiatives have been undertaken to develop more targeted anti-cancer therapies; of these, CAR T cell therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Immunotherapies essentially make the use of body’s own immune system, or its components, to fight against cancer. Over the years, different classes of immunotherapies have emerged as an alternative for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).

CAR-T cell therapy, which is a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. Overall, this highly specific and promising form of cell therapy, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipeline of the companies in this domain. Given the consistent increase in number of CAR T cell therapies being developed and launched, the CAR T cell therapy market is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.

CAR T Cell Therapy Market Share Insights

The CAR T cell therapy market report presents an in-depth analysis of various CAR T cell therapy companies in this domain, across different segments, as defined below:

  • Historical Trend: 2018-2023
  • Base Year: 2023
  • Forecast Period: 2024-2035
  • Market Size by 2035: $25 Billion
  • CAGR: 16.6%
  • Target Indication
    • Acute Myeloid Leukemia
    • Acute Lymphoblastic Leukemia
    • Chronic Lymphocytic Leukemia
    • Generalized Myasthenia Gravis
    • Hodgkin's Lymphoma
    • Multiple Myeloma
    • Non-Hodgkin's Lymphoma
    • Ovarian Cancer
    • Renal Cell Carcinoma
    • Others
  • Target Antigen
    • CD19
    • BCMA
    • CD19 / CD22
    • Others
  • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and North Africa
    • Rest of the World
  • Key CAR T Cell Therapy Companies Profiled
    • Alaunos Therapeutics
    • Autolus
    • Abelzeta Pharma
    • Bluebird Bio
    • Bristol Myers Squibb
    • Carsgen Therapeutics
    • Cellectis
    • Gilead Sciences
    • Innovative Cellular Therapeutics
    • Kuur Therapeutics
    • Noile-Immune Biotech
    • Novartis
    • Shanghai GeneChem
    • Sinobioway Cell Therapy
    • Takara Bio
    • Wellington Zhaotai Therapies
    • (Full list of more than 250 CAR-T cell therapy companies captured in the market landscape analysis of the report)
  • PowerPoint Presentation (Complimentary)
  • Customization Scope: 15% Free Customization
  • Excel Data Packs (Complimentary)
    • Market Landscape
    • Clinical Trial Analysis
    • Funding and Investments Analysis
    • Partnerships and Collaborations
    • Patent Analysis
    • Market Forecast and Opportunity Analysis

CAR T Cell Therapy Market Segmentation Overview

Market Share by Target Indication

This section segments the CAR T cell therapy market across different target indications, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, generalized myasthenia gravis, Hodgkin's lymphoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, renal cell carcinoma and others. Non-Hodgkin's Lymphoma holds the maximum share (more than 85%) in the current CAR T cell therapy market and is likely to dominate the market in the future as well. This can be attributed to the rapidly increasing incidence of non-Hodgkin's Lymphoma which make it the 11th most commonly diagnosed cancer globally. Further, the market for CAR-T therapies intended for the treatment of multiple myeloma is estimated to grow at an annualized rate of (CAGR 25%) during the forecasted period.

Market Share by Target Antigen

The global CAR T cell therapy market is segmented into CD19, BCMA, CD19 / CD22 and others. Owing to the success of CD19 targeting therapies (Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel)), the segment for CD19 is likely to capture the highest CAR T cell therapy market share (~70%) as compared to other target antigens in the coming years.

Market Share by Key Geographical Regions

This segment highlights the distribution of CAR T cell therapy market across key geographical regions, including North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World. It is worth highlighting that North America captures more than 40% of the current CAR T cell therapies market. Further, the market for CAR T therapies in Asia-Pacific is expected to grow at an annualized rate (CAGR 23%), during the forecasted period.

Car T Cell Therapy Market Key Insights

The market report features an extensive study of the current market landscape, market size, market share, market analysis, market forecast and future opportunities for the CAR T cell therapy companies. The CAR T-cell therapy market report highlights the efforts of several drug developers engaged in this rapidly emerging market segment of the pharmaceutical industry. Key takeaways of market research report is briefly discussed below.

Pipeline Analysis: 800+ CAR T Cell Therapy Programs in Clinical Trials

With more than 800 therapy programs in the clinical phases of development, CAR-T cell therapies have already established a strong foothold in the overall pharmaceutical industry. Further, close to 300 therapies targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development. CAR T cell therapy companies are developing therapies against several novel targets that have been analyzed in this research report. The expected launch of several promising leads over the forecast period will drive the CAR T cell therapy market growth.

An in-depth analysis of the pipeline shows that close to 10 CAR-T cell therapies have been commercialized for targeting various cancer indications. At present, of the approved CAR T cell therapies, six have been approved for several hematological malignancies in the US; these are Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™) and Ciltacabtagene Autoleucel (CARVYKTI™). The currently approved candidates target the CD19 receptor and BCMA.

Competitive Landscape of CAR-T Therapy Developers

The CAR-T cell therapy is among the most promising domains in the healthcare industry. Currently, over 190 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare. In January 2024, Kite Pharma achieves a milestone with the FDA's approval of their advancement in manufacturing process for axicabtagene ciloleucel (Yescarta®), significantly eliminating the median turnaround time.

CAR T Cell Therapy Market Trends Analysis: Increase in Funding, Patents, Partnership and Clinical Trials Activity Reflect the Rising Interest in this Industry

The rising interest of the stakeholders in this domain can be attributed to the increasing strategic alliances that have been by for the development of CAR T cell therapies over the past few years. More than 260 partnerships and collaborations have been inked between several industry / academic stakeholders in order to expedite the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 32 billion have been made by various private and public sector investors, in the last few years. Additionally, over 10,000 patents related to CAR T cell therapies have been recently filed / granted, demonstrating the continued innovation in CAR T cell therapy market.

It is worth noting that there has been a notable rise in the number of clinical trials evaluating CAR-T cell therapies. Around 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research in this domain. Among these, close to 60% of these clinical trials are actively recruiting patients to evaluate drugs for various types of oncology, non-oncological and other disorders. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR T cell therapy market size is likely to witness significant growth during the forecast period.

Target Indication Analysis: Acute Lymphoblastic Leukemia, B-Cell Lymphoma and Multiple Myeloma to Drive CAR T Cell Therapy Market Growth

According to the cancer data published by the Leukemia and Lymphoma Society in 2023, there were 59,610 new cases of leukemia, along with 89,380 new cases of lymphoma in the US. Many of the approved and clinical stage CAR T cell therapies target these hematological indications. Rising incidence and prevalence of cancer, as well as an increase in the relapse / remission rates will drive the adoption of CAR T cell therapies, driving the market growth. The developers of Idecabtagene Vicleucel (BMS) and Ciltacabtagene Autoleucel (Janssen and Legend Biotech) have published positive results from phase III trials for the treatment of multiple myeloma as earlier line of treatment compared to the currently approved status as fifth line therapies. Such developments will expand the potential market size of CAR T cell therapy market.

Regional Analysis: North America Holds the Largest Share in the Current CAR T Cell Therapy Market

Based on the regional distribution, North America held 54% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption.

By 2035, Europe is likely to capture more than 35% share of the global market share. In the UK, Yescarta® and Kymriah® have been to date provided through National Health Services’s (NHS) Cancer Drugs Fund, through which patients can get access to the approved drugs that have not received approval from National Institute for Health and Care Excellence (NICE) on their cost-effectiveness. However, in 2023 Yescarta (Axicabtagene Ciloleucel) became the first CAR T cell therapy to receive approval from NICE to be provided to the patients through NHS. As such, the European market will continue to grow at a healthy CAGR during the forecast period.

Market Forces Analysis: Therapy Price and Manufacturing Challenges Likely to Slow Down the CAR T Therapy Market Growth

Manufacturing biologics and cell therapies is considerably complex, as compared to small molecule drugs. The high manufacturing cost also contributes to the high price of the therapy, essentially leading to limited adoption in case of unavailability of reimbursement. In 2021, BMS faced manufacturing bottleneck for its CAR-T idecabtagene vicleucel (ABECMA®), driven by shortage of viral vectors in addition to other reasons. In 2022, Janseen and Legend Biotech rolled out their CAR-T ciltacabtagene autoleucel (CARVYKTI ®) in a phased manner in the US instead of a nationwide launch owing to manufacturing limitations.

These challenges may be temporary as the market matures and is supported by the cell therapy contract manufacturers.

Key Companies Involved in CAR T Cell Therapy Market

Examples of key CAR T cell therapy companies (the complete list of companies is available in the full report) include Alaunos Therapeutics, Autolus, Abelzeta Pharma, Bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Kuur Therapeutics, Noile-Immune Biotech, Novartis, Shanghai GeneChem, Sinobioway Cell Therapy, Takara Bio and Wellington Zhaotai Therapies. This global CAR T cell therapy market research report includes an easily searchable excel database of all the companies that are developing CAR T cell therapies.

Recent Developments in the Car T Cell Therapy Market

Several recent developments have taken place in the field of CAR T cell therapy. the analyst has outlined some of these initiatives below. These developments substantiate the overall market trends that have been outlined in the analysis.

  • In February 2024, Astellas entered into a strategic agreement with Kelonia with an aim to develop CAR-T cell therapy by combining their iGPS system with later company’s ACCEL technology.
  • In January 2024, China approved Inaticabtagene Autoleucel, a next generation CD19 targeting CAR-T cell therapy, for the treatment of patients suffering from relapsed or refractory B-cell acute lymphoblastic leukemia.
  • In October 2023, the Central Drugs Standard Control Organization approved NexCAR19, a next generation CAR-T cell therapy, for the treatment of patients suffering from advanced lymphoma or leukemia.

Car T Cell Therapy Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different geographies. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, CAR T Cell Therapy Market (5th Edition), industry trends and global forecasts till 2035.
  • An outline of the systematic research methodology adopted to conduct the study on CAR T cell therapy, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
  • An overview of economic factors that impact the overall CAR T cell therapy industry, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured during the research, offering a high-level view on the current landscape of CAR T cell therapy market and its likely evolution in the short to mid and long term.
  • A general overview of CAR T cell therapies, along with its comparison with T-cell immunotherapies. Additionally, it features the historical evolution and advancements in the manufacturing of CAR-T cell therapies. Further, it highlights the challenges faced by CAR-T cell therapy developers that are anticipated to play a crucial role in shaping the future of CAR-T cell therapies.
  • A detailed assessment of the current market landscape of CAR-T cell therapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).
  • An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to haematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
  • A detailed analysis of completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
  • Elaborate profiles of the several leading players in the domain of CAR T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, technology portfolio (if available), recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, the analyst has provided details of the strategic / venture capital investments made in these companies.
  • An analysis of various types of partnership that have been inked between several stakeholders in the CAR T cell therapy industry, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
  • An in-depth analysis of the factors that can impact the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to the model, the analyst has provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • Detailed projections of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).
  • Detailed projections of the current and future CAR T-cell therapy market across type of target antigen, such as CD19, BCMA, CD19 / CD22 and others.
  • Detailed projections of the current and future CAR T cell therapy market across leading players.
  • Detailed projections of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.
  • A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), Ciltacabtagene Autoleucel (CARVYKTI™) and others.

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the CAR T cell therapy market, over the forecast period. Based on multiple relevant parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period.

The CAR T cell therapy market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as target indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis, Renal Cell Carcinoma and Others), target antigens (CD19, BCMA, CD19 / CD22 and Others), key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World), key players and sales forecast. In order to account for future uncertainties and to add robustness to the model, the analyst has provided three CAR T cell therapy market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the CAR T cell therapy market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (Arranged based on the seniority level):

  • Former Chief Executive Officer, Small Company, Netherlands
  • Chief Executive Officer, Founder and Chairman, Mid-sized Company, China
  • Former Chief Operating Officer, Small Company, France
  • Former Vice President, Large Company, US
  • Former Vice President Immuno-Oncology, Small Company, Belgium
  • Director Business Development, Small Company, US
  • Former Competitive Intelligence Manager, Small Company, France
  • Professor, Non-industry, China
  • Assistant Professor, Non-industry, US

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this CAR T cell therapy market report are in USD, unless otherwise specified.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of T-cell Immunotherapies
5.2.1. Historical Evolution
5.2.2. Key Considerations for Developing T-cell Immunotherapies
5.2.3. Strategies Employed for the Redirection of T-cells
5.2.4. Manufacturing of Engineered T-cells
5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
5.3.1. Development History
5.3.2. Structure of CAR
5.3.2.1. Ectodomain
5.3.2.2. Transmembrane (TM) Domain
5.3.2.3. Endodomain
5.3.3. Development of CAR-T Cells
5.3.4. Universal CAR-T Cells
5.3.5. Route of Administration
5.3.6. Challenges Associated with CAR-T Cell Therapies
5.3.6.1. Competitive Risks
5.3.6.2. Clinical Risks
5.3.6.3. Regulatory Risks
5.3.6.4. Commercial Risks
5.4. Concluding Remarks
6. CAR-T CELL THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Market Landscape
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Type of Therapy
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Phase of Development and Therapeutic Area
6.2.6. Analysis by Key Target Indication
6.2.7. Analysis by Key Target Antigen
6.2.8. Analysis by Source of T-cells
6.2.9. Analysis by Phase of Development and Source of T-cells
6.2.10. Analysis by Route of Administration
6.2.11. Analysis by Dosing Frequency
6.2.12. Analysis by Target Patient Population
6.2.13. Most Active Industry Players: Analysis by Number of Therapies
6.2.14. Most Active Non-Industry Players: Analysis by Number of Therapies
6.3. CAR-T Cell Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors
7.3. CAR-T Therapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Type of Co-Stimulatory Domain
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
8.3.3. Analysis by Trial Status
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Trial Phase
8.3.6. Analysis of Enrolled Patient Population by Trial Phase
8.3.7. Analysis by Target Patient Population
8.3.8. Analysis by Type of Sponsor / Collaborator
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.12. Analysis by Key Focus Area
8.3.13. Analysis by Geography
9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Geographical Location of KOLs
9.4.4. KOL Activeness versus KOL Strength
9.4.5. Most Prominent KOLs: Analysis by RA score
9.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Alaunos Therapeutics
10.3. Autolus
10.4. Bluebird Bio
10.5. Bristol Myers Squibb
10.6. Carsgen Therapeutics
10.7. Cellectis
10.8. AbelZeta Pharma
10.9. Gilead Sciences
10.10. Innovative Cellular Therapeutics
10.11. Kuur Therapeutics
10.12. Noile-Immune Biotech
10.13. Novartis
10.14. Shanghai GeneChem
10.15. Sinobioway Cell Therapy
10.16. Takara Bio
10.17. Wellington Zhaotai Therapies
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapies: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Most Popular Therapies: Analysis by Number of Partnerships
11.3.6. Most Active Industry Players: Analysis by Number of Partnerships
11.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
11.3.8. Analysis by Geography
11.3.8.1. Intercontinental and Intracontinental Agreements
11.3.8.2. International and Local Agreements
12. FUNDING AND INVESTMENTS ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapies: Funding and Investment Analysis
12.3.1. Analysis by Year of Funding
12.3.2. Analysis of Amount Invested by Year
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of Investor
12.3.5. Most Active Players: Analysis by Amount Invested
12.3.5. Most Active Players: Analysis by Number of Funding Instances
12.3.7. Most Active Players: Analysis by Amount Invested
12.3.8. Most Active Investors: Analysis by Amount Invested
12.3.9. Most Active Investors: Analysis by Number of Funding Instances
12.3.10. Analysis by Geography
12.3.10.1. Analysis of Number of Instances by Geography
12.3.10.2. Analysis of Amount Invested by Geography
13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. CAR-T Cell Therapies: Patent Analysis
13.3.1. Analysis by Patent Publication Year
13.3.2. Analysis by Patent Application Year
13.3.3. Analysis by Patent Jurisdiction
13.3.4. Analysis by Type of Player
13.3.5. Analysis by CPC Symbols
13.3.6. Leading Industry Players: Analysis by Number of Patents
13.3.7. Leading Non-Industry Players: Analysis by Number of Patents
13.3.8. Leading Individual Assignees: Analysis by Number of Patents
13.3.9. Patent Benchmarking Analysis
13.3.9.1. Analysis by Patent Characteristics
13.3.9.2. Patent Valuation
13.3.9.3. Leading Patents by Number Of Citations
14. CASE STUDY: CELL THERAPY MANUFACTURING
14.1. Chapter Overview
14.2. Overview of Cell Therapy Manufacturing
14.3. Cell Therapy Manufacturing Models
14.3.1. Centralized Manufacturing Model
14.3.2. Decentralized Manufacturing Model
14.4. Scalability of Cell Therapy Manufacturing Processes
14.4.1. Scale-Up
14.4.2. Scale-Out
14.5. Types of Cell Therapy Manufacturers
14.6. Key Challenges Related to Manufacturing of Cell Therapies
14.7. Key Considerations for Cell Therapy Manufacturing
14.7.1. Characterization
14.7.2. Cost of Goods
14.8. Automation of Cell Therapy Manufacturing Process
14.9. Cell Therapy Manufacturing Supply Chain
14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
14.11. Regulatory Landscape
14.12. Future Perspectives
15. COST PRICE ANALYSIS
15.1 Chapter Overview
15.2. Factors Contributing to the High Price of Cell / Gene Therapies
15.3. Pricing Models for T-cell Immunotherapies
15.3.1. Based on Associated Costs
15.3.2. Based on Availability of Competing Products
15.3.3. Based on Patient Population
15.3.4. Based on Opinions of Industry Experts
15.4. Reimbursement related Considerations for T-cell Immunotherapies
15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. GLOBAL CAR-T CELL THERAPY MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035), till 2035
17.4. Scenario Analysis
17.4.1. Conservative Scenario
17.4.2. Optimistic Scenario
17.5. CAR-T Cell Therapy Market: Drug-wise Sales Forecast, Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.6. Key Market Segmentations
18. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024, 2030 and 2035
18.3.1. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.2. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Historical Trends and Future Estimates, Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.3. CAR-T Cell Therapy Market for Multiple Myeloma: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.4. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.5. CAR-T Cell Therapy Market for Other Indications: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.6. Data Triangulation and Validation
19. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024, 2030 and 2035
19.3.1. CAR-T Cell Therapy Market for CD19: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.2. CAR-T Cell Therapy Market for BCMA: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.3. CAR-T Cell Therapy Market for Other Target Antigens: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.4. Data Triangulation and Validation
20. CAR-T CELL THERAPY MARKET, BY KEY PLAYERS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Key Players
20.4. Data Triangulation and Validation
21. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
21.3.1. CAR-T Cell Therapy Market in North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.2. CAR-T Cell Therapy Market for Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.3. CAR-T Cell Therapy Market for Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.4. CAR-T Cell Therapy Market for Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.4. Data Triangulation and Validation
22. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS
23. PROMOTIONAL ANALYSIS
23.1. Chapter Overview
23.2. Channels Used for Promotional Campaigns
23.3. Summary of Product Website Analysis
23.4. Summary of Patient Support Services and Informative Downloads
23.5. Kymriah: Promotional Analysis
23.5.1. Drug Overview
23.5.2. Product Website Analysis
23.5.2.1. Message for Healthcare Professionals
23.5.2.2. Message for Patients
23.5.2.3. Informative Downloads
23.5.3. Patient Support Services
23.6. Yescarta: Promotional Analysis
23.6.1. Drug Overview
23.6.2. Product Website Analysis
23.6.2.1. Message for Healthcare Professionals
23.6.2.2. Message for Patients
23.6.2.3. Informative Downloads
23.6.3. Patient Support Services
23.7. Tecartus: Promotional Analysis
23.7.1. Drug Overview
23.7.2. Product Website Analysis
23.7.2.1. Message for Healthcare Professionals
23.7.2.2. Message for Patients
23.7.2.3. Informative Downloads
23.7.3. Patient Support Services
23.8. Breyanzi: Promotional Analysis
23.8.1. Drug Overview
23.8.2. Product Website Analysis
23.8.2.1. Message for Healthcare Professionals
23.8.2.2. Message for Patients
23.8.2.3. Informative Downloads
23.8.3. Patient Support Services
23.9. Abecma: Promotional Analysis
23.9.1. Drug Overview
23.9.2. Product Website Analysis
23.9.2.1. Message for Healthcare Professionals
23.9.2.2. Message for Patients
23.9.2.3. Informative Downloads
23.9.3. Patient Support Services
23.10. Carvykti: Promotional Analysis
23.10.1. Drug Overview
23.10.2. Product Website Analysis
23.10.2.1. Message for Healthcare Professionals
23.10.2.2. Message for Patients
23.10.2.3. Informative Downloads
23.10.3. Patient Support Services
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Glycostem Therapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript
24.3. Gracell Biotechnologies
24.3.1. Company Snapshot
24.3.2. Interview Transcript
24.4. TxCell
24.4.1. Company Snapshot
24.4.2 Interview Transcript
24.5. Kite Pharma
24.5.1. Company Snapshot
24.5.2. Interview Transcript
24.6. Celyad
24.6.1. Company Snapshot
24.6.2. Interview Transcript
24.7. Waisman Biomanufacturing
24.7.1. Company Snapshot
24.7.2. Interview Transcript
24.8. Theravectys
24.8.1. Company Snapshot
24.8.2. Interview Transcript
24.9. Changhai Hospital
24.9.1. Company Snapshot
24.9.2. Interview Transcript
24.10. Changhai Hospital
24.10.1. Company Snapshot
24.10.2. Interview Transcript
25. CONCLUDING REMARKS26. APPENDIX I: TABULATED DATA27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Strategies Employed for the Redirection of T-Cells
Figure 5.2 T-Cell Manufacturing: General Procedure
Figure 5.3 Development History of CAR-T cells
Figure 5.4 Structure of Chimeric Antigen Receptor
Figure 5.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 5.6 CAR T-Cell Therapies: Development Process
Figure 5.7 Challenges Associated with CAR T-Cell Therapies
Figure 6.1 CAR T Cell Therapy: Distribution by Phase of Development
Figure 6.2 CAR T Cell Therapy: Distribution by Therapeutic Area
Figure 6.3 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Figure 6.4 CAR T Cell Therapy: Distribution by Key Target Indication
Figure 6.5 CAR T Cell Therapy: Distribution by Key Target Antigen
Figure 6.6 CAR T Cell Therapy: Distribution by Source of T- Cells
Figure 6.7 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cells
Figure 6.8 CAR T Cell Therapy: Distribution by Route of Administration
Figure 6.9 CAR T Cell Therapy: Distribution by Dosing Frequency
Figure 6.10 CAR T Cell Therapy: Distribution by Target Patient Segment
Figure 6.11 CAR T Cell Therapy: Distribution by Type of Therapy
Figure 6.12 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 6.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 6.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 6.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 6.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters
Figure 6.17 CAR T Cell Therapy: Distribution by Company Size and Location of Headquarters
Figure 7.1 CAR T Cell Therapy: Popular Targets in Hematological Malignancies
Figure 7.2 CAR T Cell Therapy: Popular
Figure 7.3 CAR-Construction: Distribution by Generation of CAR
Figure 7.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.5 CAR-Construction: Distribution by Type of Virus Used
Figure 7.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 8.1 Clinical Trial Analysis: Scope and Methodology
Figure 8.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 8.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 8.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.10 Clinical Trial Analysis: Distribution by Study Design
Figure 8.11 Most Active Players: Distribution by Number of Registered Trials
Figure 8.12 Most Active Players: Distribution by Number of Registered Trials
Figure 8.13 Clinical Trial Analysis: Key Focus Areas
Figure 8.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 9.1 KOL Analysis: Distribution by Type of Organization
Figure 9.2 KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 KOL Analysis: Distribution by Qualification
Figure 9.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 9.5 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 Most Prominent KOLs: Distribution by RA Score
Figure 9.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015- 2022
Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5. Most Popular Therapies: Distribution by Number of Partnerships
Figure 11.6. Most Active Industry Players: Distribution by Number of Partnerships
Figure 11.7. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 11.8. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 11.8. Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Distribution of Number of Instances by Year, Pre 2019-2024
Figure 12.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2019-2023 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution by Type of Investor
Figure 12.6 Most Active Players: Distribution by Number of Instances
Figure 12.7 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 12.8 Most Active Investors: Distribution by Number of Instances
Figure 12.9 Most Active Investors: Distribution by Amount Invested
Figure 12.10 Funding and Investment Analysis: Distribution of Number of Instances by Geography
Figure 12.11 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, Pre-2018-2024
Figure 13.3 Patent Analysis: Distribution by Type of Patent and Patent Publication Year
Figure 13.4 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.5 Patent Analysis: Distribution by Top CPC Sections
Figure 13.6 Patent Analysis: Cumulative Distribution by Type of Applicant
Figure 13.7 Leading Industry Players: Distribution by Number of Patents
Figure 13.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 13.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.10 Top CPC Codes: Benchmarking by Leading Industry Players
Figure 13.11 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 13.12 Patent Analysis: Distribution by Patent Age
Figure 13.13 Patent Analysis: Valuation Analysis
Figure 14.1 Steps for Manufacturing Cell Therapies
Figure 14.2 Centralized Manufacturing: Process Model
Figure 14.3 Decentralized Manufacturing: Process Model
Figure 14.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 14.5 Cell Therapy: Challenges and Drivers
Figure 14.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 14.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 14.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 15.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 16.1. CAR-T Cell Therapies: Market Drivers
Figure 16.2. CAR-T Cell Therapies: Market Restraints
Figure 16.3. CAR-T Cell Therapies: Market Opportunities
Figure 16.4. CAR-T Cell Therapies: Market Challenges
Figure 17.1. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 17.2. Global CAR-T Cell Therapy Market, 2024-2035: Conservative Scenario (USD Billion)
Figure 17.3. Global CAR-T Cell Therapy Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 18.1. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024, 2030 and 2035
Figure 18.2. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.3. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Historical Trends and Future Estimates, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.4. CAR-T Cell Therapy Market for Multiple Myeloma: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.5. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.6. CAR-T Cell Therapy Market for Other Indications: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.1. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024, 2030 and 2035
Figure 19.2. CAR-T Cell Therapy Market for CD19: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.3. CAR-T Cell Therapy Market for BCMA: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.4. CAR-T Cell Therapy Market for Other Target Antigens: Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.1. CAR-T Cell Therapy Market: Distribution by Key Player, 2024, 2030 and 2035
Figure 21.1. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
Figure 21.2. CAR-T Cell Therapy Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.3 CAR-T Cell Therapy Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.4 CAR-T Cell Therapy Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.5. CAR-T Cell Therapy Market in Latin America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.6 CAR-T Cell Therapy Market in Middle East and North Africa, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.7 CAR-T Cell Therapy Market in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.1 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, till 2035 (USD Million)
Figure 22.2 CAR-T Cell Therapy Market for Yescarta (axicabtagene ciloleucel): Sales Forecast, till 2035 (USD Million)
Figure 22.3 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel): Sales Forecast, till 2035 (USD Million)
Figure 22.4 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121): Sales Forecast, till 2035 (USD Million)
Figure 22.5 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel): Sales Forecast, till 2035 (USD Million)
Figure 22.6 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, till 2035 (USD Million)
Figure 22.7 CAR-T Cell Therapy Market for Carteyva (Relmacabtagene autoleucel / JWCAR029): Sales Forecast, till 2035 (USD Million)
Figure 22.8 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, till 2035 (USD Million)
Figure 22.9 CAR-T Cell Therapy Market for CAR-T-CD19 Cells: Sales Forecast, till 2035 (USD Million)
Figure 22.10 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, till 2035 (USD Million)
Figure 22.11 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, till 2035 (USD Million)
Figure 22.12 CAR-T Cell Therapy Market for Inaticabtagene Autoleucel (CNCT19 / HY001): Sales Forecast, till 2035 (USD Million)
Figure 22.13 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, till 2035 (USD Million)
Figure 22.14 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, till 2035 (USD Million)
Figure 22.15 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast, till 2035 (USD Million)
Figure 22.16 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, till 2035 (USD Million)
Figure 22.17 CAR-T Cell Therapy Market for AUTO1: Sales Forecast, till 2035 (USD Million)
Figure 22.18 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T): Sales Forecast, till 2035 (USD Million)
Figure 22.19 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T): Sales Forecast, till 2035 (USD Million)
Figure 22.20 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.21 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.22 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.23 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.24 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, till 2035 (USD Million)
Figure 22.25 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, till 2035 (USD Million)
Figure 22.26 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.27 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.28 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, till 2035 (USD Million)
Figure 22.29 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, till 2035 (USD Million)
Figure 22.30 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 22.31 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T / TAA05: Sales Forecast, till 2035 (USD Million)
Figure 22.32 CAR-T Cell Therapy Market for CT053: Sales Forecast, till 2035 (USD Million)
Figure 22.33 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, till 2035 (USD Million)
Figure 22.34 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, till 2035 (USD Million)
Figure 22.35 CAR-T Cell Therapy Market for Equecabtagene Autoleucel (CT103A): Sales Forecast, till 2035 (USD Million)
Figure 22.36 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, till 2035 (USD Million)
Figure 22.37 CAR-T Cell Therapy Market for CTX110: Sales Forecast, till 2035 (USD Million)
Figure 22.38 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, till 2035 (USD Million)
Figure 22.39 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, till 2035 (USD Million)
Figure 22.40 CAR-T Cell Therapy Market for NexCAR19: Sales Forecast, till 2035 (USD Million)
Figure 23.1 Channels Used for Promotional Campaigns
Figure 23.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 23.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 23.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 23.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 23.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 23.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 23.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 23.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 23.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 23.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 23.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 23.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 23.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 23.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 23.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 23.17 Product Website Analysis: Abecma, Messages for Patients
Figure 23.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 23.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 23.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 23.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 25.1 Concluding Remarks: Market Landscape
Figure 25.2 Concluding Remarks: Clinical Trial Analysis
Figure 25.3 Concluding Remarks: Key Opinion Leaders
Figure 25.4 Concluding Remarks: Partnerships & Collaborations
Figure 25.5 Concluding Remarks: Funding and Investment Analysis
Figure 25.6 Concluding Remarks: Patent Analysis
Figure 25.7 Concluding Remarks: Market Forecast
LIST OF TABLES
Table 5.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 5.2 FDA Approved Antibody based Cancer Therapeutics
Table 5.3 Key Characteristics of CAR-T Cells
Table 5.4 Comparison of First and Second-Generation CAR-Ts
Table 5.5 CD19 CAR-T Cells: Preclinical Results
Table 5.6 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 6.1 CAR T Cell Therapy: Clinical Pipeline
Table 6.2 CAR T Cell Therapy: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 6.3 CAR T Cell Therapy: Preclinical Pipeline
Table 6.4 List of CAR-T Cells Developers
Table 6.5 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 10.1 Leading CAR-T Cell Therapy Developers
Table 10.2 Alaunos Therapeutics: Company Profile
Table 10.3 Autolus: Company Profile
Table 10.4 Bluebird Bio: Company Profile
Table 10.5 Bristol Myers Squibb: Company Profile
Table 10.6 Carsgen Therapeutics: Company Profile
Table 10.7 Cellectis: Company Profile
Table 10.8 AbelZeta Pharma: Company Profile
Table 10.9 Gilead Sciences: Company Profile
Table 10.10 Innovative Cellular Therapeutics: Company Profile
Table 10.11 Kuur Therapeutics: Company Profile
Table 10.12 Noile-Immune Biotech: Company Profile
Table 10.13 Novartis: Company Profile
Table 10.14 Shanghai GeneChem: Company Profile
Table 10.15 Sinobioway Cell Therapy: Company Profile
Table 10.16 Takara Bio: Company Profile
Table 10.17 Wellington Zhaotai Therapies: Company Profile
Table 11.1 CAR T Cell Therapy: List of Partnerships and Collaborations, 2000-2022
Table 12.1 CAR T Cell Therapy: Funding and Investments, 2000-2024
Table 12.2 CAR T Cell Therapy: Summary of Investments
Table 13.1 Patent Analysis: Prominent CPC Symbols
Table 13.2 Patent Analysis: Most Popular CPC Symbols
Table 13.3 Patent Analysis: List of Top CPC Symbols
Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.1 Assessment Strategies for Different Manufacturing Processes
Table 14.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 14.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 15.1 Price of Marketed Gene / Cell Therapies
Table 15.2 Price of Marketed Targeted Drugs
Table 15.3 CAR T Cell Therapy: Expert Opinions on Pricing
Table 15.4 CAR T Cell Therapy: Reimbursement Landscape
Table 17.1 CAR T Cell Therapy: List of Forecasted Molecules
Table 17.2 Kymriah / Tisagenlecleucel (Novartis): Net Present Value (USD Million)
Table 17.3 Kymriah / Tisagenlecleucel (Novartis): Value Creation Analysis (USD Million)
Table 17.4 Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences): Net Present Value (USD Million)
Table 17.5 Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 17.6 Tecartus / Brexucabtagene Autoleucel: (Gilead Sciences): Net Present Value (USD Million)
Table 17.7 Tecartus / Brexucabtagene Autoleucel: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 17.8 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 17.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 17.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 17.11 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 17.12 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (BristolMyers Squibb): Net Present Value (USD Million)
Table 17.13 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (BristolMyers Squibb): Value Creation Analysis (USD Million)
Table 17.14 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JWTherapeutics): Net Present Value (USD Million)
Table 17.15 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JWTherapeutics): Value Creation Analysis (USD Million)
Table 17.16 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 17.17 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicineTechnology): Value Creation Analysis (USD Million)
Table 17.18 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 17.19 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 17.20 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 17.21 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 17.22 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 17.23 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 17.24 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 17.25 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 17.26 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 17.27 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 17.28 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 17.29 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 17.30 TAK-007 (Takeda): Net Present Value (USD Million)
Table 17.32 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 17.33 AUTO1 (Autolus): Net Present Value (USD Million)
Table 17.34 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 17.35 AUTO3 (Autolus): Net Present Value (USD Million)
Table 17.36 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 17.37 CD19 CAR-T (BiorayLaboratories): Net Present Value (USD Million)
Table 17.38 CD19 CAR-T (BiorayLaboratories): Value Creation Analysis (USD Million)
Table 18.39 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.40 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 17.41 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 17.42 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 17.43 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 17.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 17.45 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 17.46 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 17.47 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 17.48 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 17.49 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 17.50 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 17.51 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 17.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 17.53 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 17.54 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 17.55 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 17.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis(USD Million)
Table 17.57 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 17.58 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 17.59 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 17.60 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 17.61 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 17.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 17.63 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 17.64 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 17.65 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 17.66 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 17.67 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 17.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 17.69 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 17.70 CT053 (CARsgen Therapeutics): Value Creation Analysis (USD Million)
Table 17.71 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 17.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 17.73 BCMA targeted prime CAR-T cells (Chongqing PrecisionBiotechnology): Net Present Value (USD Million)
Table 17.74 BCMA targeted prime CAR-T cells (Chongqing PrecisionBiotechnology): Value Creation Analysis (USD Million)
Table 17.75 ALLO-605 (AllogeneTherapeutics): Net Present Value (USD Million)
Table 17.76 ALLO-605 (AllogeneTherapeutics): Value Creation Analysis (USD Million)
Table 17.77 WU CART 007 (WUGEN): Net Present Value (USD Million)
Table 17.78 WU CART 007 (WUGEN): Value Creation Analysis (USD Million)
Table 17.79 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 17.80 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 17.81 NexCAR19 (ImmunoACT): Net Present Value (USD Million)
Table 17.82 NexCAR19 (ImmunoACT): Value Creation Analysis (USD Million)
Table 26.1 CAR T Cell Therapy: Distribution by Phase of Development
Table 26.2 CAR T Cell Therapy: Distribution by Therapeutic Area
Table 26.3 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Table 26.4 CAR T Cell Therapy: Distribution by Key Target Indication
Table 26.5 CAR T Cell Therapy: Distribution by Key Target Antigen
Table 26.6 CAR T Cell Therapy: Distribution by Source of T-Cells
Table 26.7 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cells
Table 26.8 CAR T Cell Therapy: Distribution by Route of Administration
Table 26.9 CAR T Cell Therapy: Distribution by Dosing Frequency
Table 26.10 CAR T Cell Therapy: Distribution by Target Patient Segment
Table 26.11 CAR T Cell Therapy: Distribution by Type of Therapy
Table 26.12 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Table 26.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 26.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Table 26.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 26.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters
Table 26.17 CAR T Cell Therapy: Distribution by Company Size and Location of Headquarters
Table 26.18 CAR-Construction: Distribution by Generation of CAR
Table 26.19 CAR-Construction: Distribution by Type of scFv Antibody
Table 26.20 CAR-Construction: Distribution by Type of Virus Used
Table 26.21 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Table 26.22 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Table 26.23 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 26.24 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 26.25 Clinical Trial Analysis: Distribution by Trial Status
Table 26.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 26.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 26.29 Clinical Trial Analysis: Distribution by Target Patient Population
Table 26.30 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.31 Clinical Trial Analysis: Distribution by Study Design
Table 26.32 Most Active Players: Distribution by Number of Registered Trials
Table 26.33 Most Active Players: Distribution by Number of Registered Trials
Table 26.34 Clinical Trial Analysis: Key Focus Areas
Table 26.35 Clinical Trial Analysis: Distribution of Trials by Geography
Table 26.36 KOL Analysis: Distribution by Type of Organization
Table 26.37 KOL Analysis: Distribution by Affiliated Organization
Table 26.38 KOL Analysis: Distribution by Qualification
Table 26.39 CAR T-Cell Therapies: Geographical Distribution of KOLs
Table 26.40 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 26.41 Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 26.42 Most Prominent KOLs: Distribution by RA Score
Table 26.43 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 26.44 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 26.45 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015- 2022
Table 26.46 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.47 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.48 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.49 Most Popular Therapies: Distribution by Number of Partnerships
Table 26.50 Most Active Industry Players: Distribution by Number of Partnerships
Table 26.51 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 26.52 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 26.53 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 26.54 Funding and Investment Analysis: CumulativeDistribution of Number of Instances by Year, Pre 2019-2024
Table 26.55 Funding and Investment Analysis: CumulativeDistribution of Amount Invested by Year, 2019-2023 (USD Million)
Table 26.56 Funding and Investment Analysis: Distribution by Type of Funding
Table26.57 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table26.58 Funding and Investment Analysis: Distribution by Type of Investor
Table 26.59 Most Active Players: Distribution by Number of Instances
Table 26.60 Most Active Players: Distribution by AmountInvested (USD Million)
Table 26.61 Most Active Investors: Distribution by Number of Instances
Table 26.62 Most Active Investors: Distribution by Amount Invested
Table 26.63 Funding and Investment Analysis: Distribution of Number of Instances by Geography
Table 26.64 Funding and Investment Analysis: Distribution of Amount Invested by Geography(USD Million)
Table 26.65 Patent Analysis: Distribution by Type of Patent
Table 26.66 Patent Analysis: Cumulative Distribution by Patent Publication Year, Pre-2018-2024
Table 26.67 Patent Analysis: Distribution by Type of Patent and Patent Publication Year
Table 26.68 Patent Analysis: Distribution by Patent Jurisdiction
Table 26.69 Patent Analysis: Distribution by Top CPC Sections
Table 26.70 Patent Analysis: Cumulative Distribution by Type of Applicant
Table 26.71 Leading Industry Players: Distribution by Number of Patents
Table 26.72 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.73 Leading Individual Assignees: Distribution by Number of Patents
Table 26.74 Top CPC Codes: Benchmarking by Leading Industry Players
Table 26.75 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Codes)
Table 26.76 Patent Analysis: Distribution by Patent Age
Table 26.77 Patent Analysis: Valuation Analysis

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 920th Hospital of Joint Logistics Support Force
  • AbbVie Ventures
  • AbCellera
  • AbCheck
  • AbClon
  • Abound Bio
  • Abzena
  • Ac?badem Atunizade Hospital
  • Ac?badem Labcell
  • Acibadem University
  • ACROBiosystems
  • AdAlta
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Adimab
  • Affiliated Hospital of Jiangnan University
  • Affiliated Hospital of Jiangsu University
  • Affiliated Hospital to Academy of Military Medical Sciences
  • Affiliated Zhongshan Hospital of Dalian University
  • AffyImmune Therapeutics
  • AGC Biologics
  • Agreen Biotech
  • AK (Suzhou) Biomedical
  • Alaunos Therapeutics
  • Aleta Biotherapeutics
  • Alexandria Venture Investments
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Alpha Biopharma
  • Amgen Ventures
  • Anhui Anke Biotechnology
  • Anhui Provincial Hospital
  • Antion Biosciences
  • Appia Bio
  • Arbele
  • Arcellx
  • Astellas Pharma
  • Astrazeneca
  • Atara Biotherapeutics
  • August Pi and Sunyer Biomedical Research Institute
  • Aurora Biopharma
  • Autolus
  • Avencell
  • Bambino Gesù Hospital and Research Institute
  • Bayer
  • Baylor College of Medicine
  • Be The Match BioTherapies
  • Beam Therapeutics
  • Beijing 302 Hospital
  • Beijing Biohealthcare Biotechnology
  • Beijing Boren Hospital
  • Beijing Cancer Hospital
  • Beijing Chao Yang Hospital
  • Beijing Children's Hospital
  • Beijing Doing Biomedical
  • Beijing GoBroad Hospital Management
  • Beijing HuiNengAn Biotech
  • Beijing Immunochina Medical Science & Technology
  • Beijing Sanbo Brain Hospital
  • Beijing Tsinghua Chang Gung Hospital
  • Beike Biotechnology
  • Bellicum Pharmaceuticals
  • Beth Israel Deaconess Medical Center (BIDMC)
  • Bio-Gene Technology
  • Bioceltech Therapeutics
  • BioLife Solutions
  • Bionomics
  • BioNTech
  • Bioray Laboratories
  • Biosceptre
  • Bluebird Bio
  • Boya Jiyin
  • BoYuan RunSheng Pharma (Hangzhou)
  • Bristol-Myers Squibb
  • Cabaletta Bio
  • Cabaret Biotech
  • Calibr
  • California Institute for Regenerative Medicine (CIRM)
  • Cancer Prevention Research Institute of Texas
  • Cancer Research Technology
  • Cancer Research UK
  • Carbiogene Therapeutics
  • Caribou Biosciences
  • Carina Biotech
  • Caring Cross
  • Carisma Therapeutics
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Cartherics
  • Case Comprehensive Cancer Center
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Design Labs
  • Cellectis
  • Cellex Patient Treatment
  • CELLforCURE
  • CellPoint
  • Cellular Biomedicine Group
  • Cellvec
  • Celularity
  • Celyad Oncology
  • Center for International Blood and Marrow Transplant Research
  • Central South University
  • Changhai Hospital
  • Chengdu USino Technology Biology
  • Children's Hospital and Health System Foundation
  • Children's Hospital of Fudan University
  • Children's Hospital of Philadelphia
  • Children’s Hospital of Philadelphia
  • China Immunotech (Beijing) Biotechnology
  • China Meitan General Hospital
  • China Regenerative Medicine International (CRMI)
  • Chinese Academy of Sciences
  • Chinese PLA General Hospital
  • Chongqing Precision Biotech
  • Chongqing Public Health Medical Center
  • Chongqing Sidemu Biotech
  • Chongqing University Cancer Hospital
  • City of Hope Medical Center
  • CoIMMUNE
  • Cold Spring Harbor Laboratory
  • Columbia University
  • CRISPR Therapeutics
  • Cryoport
  • CureSearch for Children's Cancer
  • Curocell
  • CytoLumina Technologies
  • CytoMed Therapeutics
  • Cytovia Therapeutics
  • DAIICHI SANKYO COMPANY
  • Dana-Farber Cancer Institute
  • Dartmouth College
  • Delenex Therapeutics
  • DLR German Aerospace Center
  • Dongguan People's Hospital
  • East Clinical Center of Oncology
  • Eden BioCell
  • Editas Medicine
  • Eli Lilly
  • Elicera Therapeutics
  • Elpis Biopharmaceuticals
  • Eureka Therapeutics
  • Eutilex
  • EXUMA Biotech
  • Fate Therapeutics
  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  • Fidelity Management & Research
  • First Affiliated Hospital of Chengdu Medical College
  • First Affiliated Hospital of Harbin Medical University
  • First Affiliated Hospital of Wenzhou Medical Univeristy
  • First Affiliated Hospital of Wenzhou Medical University
  • First Affiliated Hospital of Zhejiang University
  • First Affiliated Hospital Xi'an Jiaotong University
  • First Hospital of Jilin University
  • First People's Hospital of Foshan
  • Five Prime Therapeutics
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • Fondo Social La Caixa
  • Formula Pharmaceuticals
  • Fosun Pharmaceutical
  • Fourth Hospital of Hebei Medical University
  • Fraunhofer
  • Fred Hutchinson Cancer Research
  • Fred Hutchinson Cancer Research Center
  • Fudan University
  • Fujian Medical University
  • Fundamenta Therapeutics
  • FutureGen Biopharm
  • G Plus Life Sciences
  • GE Global Research
  • GE Healthcare
  • Genentech
  • Genus Oncology
  • Gilead Sciences
  • Glycostem
  • GlyTherix
  • Gracell Biotechnologies
  • Great Ormond Street Hospital for Children NHS Foundation Trust
  • Guangdong General Hospital
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou 8th People's Hospital
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou First People's Hospital
  • H. Lee Moffitt Cancer Center and Research Institute
  • Hadassah Medical Organization
  • Harvard University
  • HCW Biologics
  • Hebei Senlang Biotechnology
  • Hebei Yanda Ludaopei Hospital
  • Hefei Binhu Hospital
  • Heidelberg University Hospital
  • Henan Cancer Hospital
  • Henan Hualong Biotechnology
  • Henan Provincial People's Hospital
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Horizon 2020
  • Horizon Discovery Group
  • Houston Methodist Hospital
  • Hrain Biotechnology
  • HuaDao (Shanghai) Biomedical
  • Huai'an Second People's Hospital
  • Huazhong University of Science and Technology
  • Hunan Provincial People's Hospital
  • Hunan Yongren Medical Innovation
  • Hunan Zhaotai Yongren Biotech
  • Hunan Zhaotai Yongren Medical Innovation
  • IASO Biotherapeutics
  • iCAR Bio Therapeutics
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • ICON
  • IIT MediTech (Jiangsu)
  • ImmunoACT
  • Imugene
  • Inhibrx
  • Innovative Cellular Therapeutics
  • Innovent Biologics
  • Institut Curie
  • Institute of Hematology & Blood Diseases Hospital
  • Institute of Hematology and Blood Transfusion
  • Instituto de Salud Carlos III
  • Intellia Therapeutics
  • Intrexon
  • Invectys
  • Janssen
  • Jiangsu Province Hospital of Traditional Chinese Medicine
  • Jiangyin People's Hospital
  • Jichi Medical University Hospital
  • Jingjiang People's Hospital
  • Jingzhou Central Hospital
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • KAEDI
  • Karolinska Institute
  • Kecellitics Biotech
  • King's College London
  • Kite Pharma (a Gilead Sciences Company)
  • Kuur Therapeutics
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Leukemia & Lymphoma Society
  • Leukemia Research Foundation
  • Life Technologies
  • Lilly Asia Ventures
  • Liminatus Pharma
  • Living Pharma
  • Lonza
  • Loyola University Medical Center
  • LUMICKS
  • Lyell Immunopharma
  • MabQuest
  • Malaghan Institute of Medical Research
  • Marino Biotechnology
  • Massachusetts General Hospital
  • MaSTherCell
  • Max Delbrück Center for Molecular Medicine
  • MaxCyte
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medical College of Wisconsin
  • MedImmune
  • Medisix Therapeutics
  • MediTrust Health
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Mie University Hospital
  • Miltenyi Biomedicine
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • Mink Therapeutics
  • Moderna
  • MolMed (acquired by AGC Biologics)
  • Mustang Bio
  • Nanfang Hospital of Southern Medical University
  • Nanjing Bioheng Biotech
  • Nanjing Children's Hospital
  • NantKwest
  • Nantong University
  • National Cancer Center Research Institute Japan
  • National Cancer Institute
  • National Heart, Lung and Blood Institute
  • National Institutes of Health (NIH)
  • National Institutes of Health Clinical Center
  • National Taiwan University Hospital
  • National University Hospital, Singapore
  • Navy General Hospital
  • NeoStem
  • Ningbo Cancer Hospital
  • NIPRO
  • Nkarta
  • Noile-Immune Biotech
  • Notch Therapeutics
  • Novartis
  • Novartis Venture Fund
  • nSAGE
  • NSF Engineering Research Center for Cell Manufacturing Technologies
  • Oncodesign Biotechnology
  • Oncora Medical
  • OncoTracker
  • Oncternal Therapeutics
  • Oncyte
  • ONK Therapeutics
  • oNKo-innate
  • ONO Pharmaceutical
  • Opus Bio
  • OrbiMed Advisors
  • Ospedale Pediatrico Bambino Gesù (OPBG)
  • Otsuka Pharmaceutical
  • Ottawa Hospital Research Institute
  • Outpace Bio
  • Overland Pharmaceuticals
  • Oxford Biomedica
  • Oxford Biotherapeutics
  • Oxford MEStar
  • panCELLa
  • Parker Institute for Cancer Immunotherapy
  • Pediatric Brain Tumor Consortium
  • Peking Union Medical College Hospital
  • Peking University People's Hospital
  • Peking University Shenzhen Hospital
  • Peking University Third Hospital
  • PeproMene Bio
  • PersonGen BioTherapeutics
  • Peter MacCallum Cancer Centre
  • Pfenex
  • Pfizer
  • PHARMALOG Institut für klinische Forschung
  • PhoreMost
  • Pieris Pharmaceuticals
  • Pierre Fabre
  • Pinze Lifetechnology
  • PLA General Hospital
  • Porton Biologics
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Pregenen
  • ProMab Biotechnologies
  • Protheragen
  • Qilu Hospital of Shandong University
  • RA Capital Management
  • Redmile Group
  • RedoxTherapeis
  • Refuge Biotechnologies
  • Regeneron Pharmaceutical
  • RenJi Hospital
  • resTORbio
  • Rockland Immunochemicals
  • Roger Williams Medical Center
  • Rosewell Park Comprehensive Cancer Center
  • Royal Adelaide Hospital Cancer Centre
  • Ruijin Hospital
  • Sabz Biomedicals
  • Sana Biotechnology
  • Sangamo Therapeutics
  • Sanofi
  • Scotia Biologics
  • Seattle Children's Hospital
  • Seattle Children's Research Institute
  • Seattle Children’s Research Institute
  • Second Affiliated Hospital of Guangzhou Medical University
  • Second Affiliated Hospital of Nanchang University
  • Second Affiliated Hospital of Suzhou University
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Second Military Medical University
  • Second Xiangya Hospital of Central South University
  • Servier
  • Shangai Cancer Institute
  • Shanghai Biomed-Union Biotechnology
  • Shanghai Bioray Laboratory
  • Shanghai Cell Therapy Group
  • Shanghai Changzheng Hospital
  • Shanghai Chest Hospital
  • Shanghai Children's Medical Center
  • Shanghai East Hospital
  • Shanghai GeneChem
  • Shanghai General Hospital
  • Shanghai International Medical Center
  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Longyao Biotechnology
  • Shanghai Ming Ju Biotechnology
  • Shanghai OriginCell Therapeutics
  • Shanghai PerHum Therapeutics
  • Shanghai Pharmaceuticals
  • Shanghai Public Health Clinical Center
  • Shanghai Simnova Biotechnology
  • Shanghai Tong Ren Hospital
  • Shanghai Tongji Hospital
  • Shanghai Ultra-T Immune Therapeutics
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shanghai Zhongshan Hospital
  • Shanxi Province Cancer Hospital
  • Shariati Hospital
  • Sheba Medical Center
  • Shenzhen Binde Biotechnology
  • Shenzhen BinDeBio
  • Shenzhen Children's Hospital
  • Shenzhen Geno-Immune Medical Institute
  • Shenzhen Hospital of Southern Medical University
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
  • Shenzhen University
  • ShiJiaZhuang Zhongxi Children Hospital
  • Shoreline Biosciences
  • Sichuan Kelun-Biotech Biopharmaceutical
  • Sichuan University
  • Simcere Pharmaceutical
  • Sinobioway Cell Therapy
  • Sistema and Russian Direct Investment Fund
  • Sorrento Therapeutics
  • Southern Medical University
  • Southwest Hospital
  • SpringWorks Therapeutics
  • St. Baldrick's Foundation
  • St. Jude Children's Research Hospital
  • Stage Cell Therapeutics
  • Stand Up To Cancer
  • Stanford University
  • Stony Brook University
  • Sun Yat-Sen University
  • Syncopation Life Sciences
  • T-Curx
  • Takara Bio
  • Takeda Pharmaceutical
  • TC BioPharm
  • TCRCure Biopharma
  • Tehran University of Medical Sciences
  • Tel Aviv Sourasky Medical Center
  • Temasek
  • Teneobio
  • Terumo BCT
  • Tessa Therapeutics
  • Texas Children's Hospital
  • The Affiliated Hospital Of Guizhou Medical University
  • The Affiliated Hospital of Xuzhou Medical University
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • The Beijing Pregene Science and Technology
  • The Children's Mercy Hospital
  • The Faris Foundation
  • The First Affiliated Hospital of Anhui Medical University
  • The First Affiliated Hospital of Dalian Medical University
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
  • The First Affiliated Hospital of Kunming Medical College
  • The First Affiliated Hospital of Nanchang University
  • The First Affiliated Hospital of Nanjing Medical University
  • The First Affiliated Hospital of Soochow University
  • The First Affiliated Hospital of University of Science and Technology of China
  • The First Affiliated Hospital of Zhejiang University
  • The First Affiliated Hospital of Zhengzhou University
  • The First Affiliated Hospital with Nanjing Medical University
  • The First People's Hospital of Changzhou
  • The First People's Hospital of Hefei
  • The First People's Hospital of Yuhang District
  • The First People's Hospital of Yunnan
  • The Fourth Hospital of Hebei Medical University
  • The General Hospital of Western Theater Command
  • The Ohio State University
  • The Pregene (ShenZhen) Biotechnology
  • The Second Affiliated Hospital of Chongqing Medical University
  • The Second Affiliated Hospital of Hainan Medical University
  • The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  • The Second Hospital of Anhui Medical University
  • The Second Hospital of Hebei Medical University
  • The Second Hospital of Nanjing Medical University
  • The Seventh Affilliated Hospital
  • The Sixth Affiliated Hospital of Wenzhou Medical University
  • The Third People's Hospital of Kunshan
  • The Wistar Institute
  • ThermoFisher Scientific
  • Tianjin Medical University
  • Tianjin Medical University General Hospital
  • Tianjin Mycure Medical Technology
  • Ticaros
  • Timmune Biotech
  • Tiziana Life Sciences
  • Tmunity Therapeutics
  • Tongji Hospital
  • Tongji University
  • TrakCel
  • Transgene
  • Transposagen Biopharmaceuticals
  • Tri-Service General Hospital
  • TriArm Therapeutics
  • Trinity College Dublin
  • Triumph Over Kid Cancer Foundation
  • Tsinghua University
  • Twist Bioscience
  • TxCell
  • Ucello Therapeutics
  • UCL Business
  • UNC Lineberger Comprehensive Cancer Center
  • Union Stem Cell & Gene Engineering
  • United States Department of Defense
  • University College London
  • University Health Network
  • University of Alberta
  • University of Birmingham
  • University of California
  • University of Colorado
  • University of Milano-Bicocca
  • University of Minnesota
  • University of Munich
  • University of North Carolina
  • University of Pennsylvania
  • University of South Australia
  • University of Southern California
  • University of Texas
  • University of Washington
  • University of Washington and Seattle Cancer Care Alliance
  • University of Washington Cancer Consortium
  • University of Zurich
  • Uppsala University
  • USHEALTH
  • UTC Therapeutics
  • UWELL Biopharma
  • V Foundation
  • VCN Biosciences
  • venBio
  • Versant Ventures
  • Vineti
  • ViroMed
  • Vitruvian Networks
  • Vivo Capital
  • Washington University
  • Weill Cornell Medical College
  • Weill Medical College of Cornell University
  • Wellington Zhaotai Therapies
  • West China Hospital
  • West China Hospital of Sichuan University
  • Wugen
  • Wuhan Bio-Raid Biotechnology
  • Wuhan Sian Medical Technology
  • Wuhan Union Hospital
  • WuXi AppTec
  • X-Body
  • Xi'An Yufan Biotechnology
  • Xiangya Hospital of Central South University
  • Xiangyang Central Hospital
  • Xijing Hospital
  • Xinhua Hospital
  • Xinqiao Hospital
  • Xuanwu Hospital
  • Xuzhou Medical University
  • Yake Biotechnology
  • Yamaguchi University
  • Yan'an Affiliated Hospital of Kunming Medical University
  • Yunnan Cancer Hospital
  • Zhejiang Provincial People's Hospital
  • Zhejiang Qixin Biotech
  • Zhejiang University
  • Zhujiang Hospital

Methodology

 

 

Loading
LOADING...

Table Information